公开(公告)号：US20240182898A1

公开(公告)日：2024-06-06

申请号：US18540306

申请日：2023-12-14

Applicant: HOFFMANN-LA ROCHE INC.

Inventor： Erik FUNDER ,  Natascha HRUSCHKA ,  Susanne KAMMLER ,  Erich Koller ,  Brian Leonard ,  Souphalone LUANGSAY ,  Susanne MOHR ,  Tobias NILSSON ,  Søren OTTOSEN ,  Lykke PEDERSEN ,  Søren RASMUSSEN ,  Steffan SCHMIDT ,  Sabine SEWING ,  Daniel Turley ,  Johanna Marie WALTHER

IPC: C12N15/113 ,  A61K31/7088 ,  A61P31/20

CPC classification number: C12N15/113 ,  A61K31/7088 ,  A61P31/20 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/3231 ,  C12N2310/341 ,  C12N2310/351

Abstract: Enhanced antisense oligonucleotides targeting Regulator of telomere elongation helicase 1 (RTEL1), leading to modulation of the expression of RTEL1 or modulation of RTEL1 activity are provided. This disclosure relates to the use of enhanced antisense oligonucleotides targeting RTEL1 for use in treating and/or preventing a hepatitis B virus (HBV) infection, in particular a chronic HBV infection. This disclosure further relates to the use of the enhanced antisense oligonucleotides targeting RTEL1 for destabilizing cccDNA, such as HBV cccDNA. A pharmaceutical composition and its use in the treatment and/or prevention of a HBV infection is also described.

公开(公告)号：US20220251556A1

公开(公告)日：2022-08-11

申请号：US17590754

申请日：2022-02-01

Applicant: HOFFMANN-LA ROCHE INC.

Inventor： Erik FUNDER ,  Natascha HRUSCHKA ,  Susanne KAMMLER ,  Erich KOLLER ,  Brian LEONARD ,  Souphalone LUANGSAY ,  Susanne MOHR ,  Tobias NILSSON ,  Søren OTTOSEN ,  Lykke PEDERSEN ,  Søren V. RASMUSSEN ,  Steffen SCHMIDT ,  Sabine SEWING ,  Daniel TURLEY ,  Johanna Marie WALTHER

IPC: C12N15/113 ,  A61K31/7088 ,  A61P31/20

Abstract: Enhanced antisense oligonucleotides targeting Regulator of telomere elongation helicase 1 (RTEL1), leading to modulation of the expression of RTEL1 or modulation of RTEL1 activity are provided. This disclosure relates to the use of enhanced antisense oligonucleotides targeting RTEL1 for use in treating and/or preventing a hepatitis B virus (HBV) infection, in particular a chronic HBV infection. This disclosure further relates to the use of the enhanced antisense oligonucleotides targeting RTEL1 for destabilizing cccDNA, such as HBV cccDNA. A pharmaceutical composition and its use in the treatment and/or prevention of a HBV infection is also described.